Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director Cyrus Taraporevala acquired 1,471.743 phantom stock units as deferred compensation, increasing his total beneficial ownership to 23,444.776 units.

Summary

• Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), acquired 1,471.743 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents thereon.
• The phantom stock units are settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The acquisition price for these derivative securities was $25.48 per unit.
• Following this transaction, Taraporevala beneficially owns a total of 23,444.776 phantom stock units.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by a director is a positive signal of aligned interests, as it ties a portion of their compensation to the company's long-term stock performance. This is a routine compensation event.

Positives

• Director Cyrus Taraporevala increased his beneficial ownership of phantom stock units by 1,471.743 units.
• The acquisition of phantom stock units as deferred compensation aligns the director's interests with long-term shareholder value.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing, reflecting a director's deferred compensation in the form of phantom stock units, a common practice in large pharmaceutical companies like Pfizer to align executive and director interests with shareholder value.

Comparison to Industry Standards

• The use of phantom stock units as deferred director's compensation is a common practice across the pharmaceutical industry and large-cap companies, aligning director incentives with long-term company performance.
• This is a standard mechanism for non-employee director compensation, comparable to practices at companies like Johnson & Johnson or Merck, which also utilize equity-based awards for their non-executive directors.

Related Party Transactions

• Acquisition of 1,471.743 phantom stock units by Director Cyrus Taraporevala as deferred director's compensation.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value through equity-based compensation.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of phantom stock units by a director as part of their deferred compensation. While it indicates alignment of interests, it does not present new information significant enough to alter an investment thesis or warrant a strong buy or sell recommendation. It's a standard insider transaction.

Keywords

Pfizer, PFE, Form 4, insider transaction, director compensation, phantom stock, equity compensation